Insights

Strategic partnerships Leverage InvVax's strong UCLA affiliation and collaborations with Trudeau Institute and Hong Kong University to position as a collaborative R&D partner for translational vaccine programs and preclinical studies with potential co-development or sponsored research opportunities.

Universal flu focus capitalize on InvVax's universal flu vaccine program and preclinical success to offer strategic advisory, joint development, or licensing discussions with larger biotech players seeking broad-coverage influenza solutions and platform validation.

Early-stage potential Target early-stage investors and partners for funding and portfolio expansion by highlighting recent preclinical milestones, revenue generation, and a clear pathway to clinical development, aligning BD pitches with risk-tolerant life-science funds.

Small team agility Position InvVax as a nimble contract research partner for rapid feasibility studies, small-scale collaborations, and focused immunology/molecular virology experiments that can complement larger CROs or academic collaborators.

Geographic and academic access Exploit Southern California presence and UCLA ecosystem to access biotech clusters, talent, and grant opportunities, offering joint venture or sponsored research models with nearby institutions and industry players seeking regional partnerships.

Similar companies to InvVax, Inc.

InvVax, Inc. Tech Stack

InvVax, Inc. uses 8 technology products and services including WordPress, MySQL, Google Workspace, and more. Explore InvVax, Inc.'s tech stack below.

  • Content Management System
  • MySQL
    Database
  • Font Awesome
    Font Scripts
  • Google Maps
    Maps
  • Slider Revolution
    Miscellaneous
  • InMotion Hosting
    Web Hosting
  • Apache
    Web Servers

InvVax, Inc.'s Email Address Formats

InvVax, Inc. uses at least 1 email format:
InvVax, Inc. Email FormatsExamplePercentage
First@inv-vax.comJohn@inv-vax.com
100%

Frequently Asked Questions

What is InvVax, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
InvVax, Inc.'s official website is inv-vax.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does InvVax, Inc. generate?

Minus sign iconPlus sign icon
As of November 2026, InvVax, Inc.'s annual revenue is estimated to be $1M - $10M.

What is InvVax, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
InvVax, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does InvVax, Inc. have currently?

Minus sign iconPlus sign icon
As of November 2026, InvVax, Inc. has approximately 4 employees across 1 continents, including North America. Key team members include Chief Executive Officer: C. M. and President / Founder: A. Y. Explore InvVax, Inc.'s employee directory with LeadIQ.

What industry does InvVax, Inc. belong to?

Minus sign iconPlus sign icon
InvVax, Inc. operates in the Biotechnology Research industry.

What technology does InvVax, Inc. use?

Minus sign iconPlus sign icon
InvVax, Inc.'s tech stack includes WordPress, MySQL, Google Workspace, Font Awesome, Google Maps, Slider Revolution, InMotion Hosting and Apache.

What is InvVax, Inc.'s email format?

Minus sign iconPlus sign icon
InvVax, Inc.'s email format typically follows the pattern of First@inv-vax.com. Find more InvVax, Inc. email formats with LeadIQ.

How much funding has InvVax, Inc. raised to date?

Minus sign iconPlus sign icon
As of November 2026, InvVax, Inc. has raised $256K in funding. The last funding round occurred on Feb 18, 2022 for $256K.

When was InvVax, Inc. founded?

Minus sign iconPlus sign icon
InvVax, Inc. was founded in 2012.
InvVax, Inc. logo

InvVax, Inc.

Biotechnology ResearchCalifornia, United States2-10 Employees

InvVax, Inc. is a biotechnology research company founded in January 2013 and based in Los Angeles, California. The firm focuses on vaccine development and maintains a strong affiliation with UCLA, reflecting its origins in academic research and access to a broad network of investigators across molecular virology, immunology, pharmacology, and clinical infectious diseases. Its stated aim is to build a novel platform for vaccines and to engage highly talented researchers in scientific, industrial, and management roles to address global health needs. In recent years, InvVax has been pursuing a universal flu vaccine program, reporting preclinical progress and collaborations with academic and research partners to demonstrate immune responses in preclinical models. The company operates within the biotechnology research sector and targets collaborators and stakeholders seeking early-stage, platform-based vaccine development beyond traditional approaches.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2012
Employees
2-10

Section iconFunding & Financials

  • $256K

    InvVax, Inc. has raised a total of $256K of funding over 6 rounds. Their latest funding round was raised on Feb 18, 2022 in the amount of $256K as a Grant.

  • $1M - $10M

    InvVax, Inc.'s revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.